StockNews.AI
NOTV
StockNews.AI
13 days

CORRECTING and REPLACING - Inotiv Reports Third Quarter Financial Results for Fiscal 2025 and Provides Business Update

1. NOTV's Q3 FY 2025 revenue rose 23.5% to $130.7 million. 2. Consolidated net loss improved to $17.6 million from $26.1 million YoY. 3. RMS revenue surged 34.1%, reflecting strong client demand. 4. Adjusted EBITDA reached $11.6 million, showing significant growth. 5. SEC investigation concluded without enforcement actions, positively impacting market perception.

Earnings
-10.5%Current Return
VS
-0.08%S&P 500
$2.1908/06 09:21 PM EDTEvent Start
$1.9608/08 04:11 AM EDTLatest Updated
31m saved
Insight
Article

FAQ

Why Bullish?

The significant revenue growth and reduced losses reflect improving business fundamentals, likely increasing investor confidence. Comparatively, similar uptrends in revenues have historically boosted share prices in the sector.

How important is it?

The article covers critical financial results and positively resolved regulatory matters, indicating strong operational performance that can influence stock price significantly.

Why Short Term?

The upcoming conference call and the positive financial results are expected to boost investor sentiment in the immediate future, similar to past earnings reports influencing stock prices shortly after announcements.

Related Companies

MMSICRLWAT
In a release issued under the same headline on August 6, 2025 by Inotiv, Inc. (NASDAQ: NOTV), please note that the amount of the recent draw request on the revolving credit facility has been corrected. The corrected release follows: – Third quarter fiscal 2025 revenue up 23.5% to $130.7 million– Year-to-date fiscal 2025 revenue increased 4.0% to $374.9 million– Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q3 FY 2025”) ended June 30, 2025, and nine months ("YTD FY 2025") ended June 30, 2025. Revenue by Segment (in millions of USD)  Three Months Ended June 30, % change (1) Nine Months Ended June 30, % change (1) 2025 2024   2025 2024   (unaudited) (unaudited)   (unaudited) (unaudited)  DSA (Discovery & Safety Assessment)$48.2  $44.2  8.9% $136.3  $135.5  0.6%RMS (Research Models & Services)$82.5  $61.6  34.1% $238.6  $224.8  6.1%Total (1)$130.7  $105.8  23.5% $374.9  $360.3  4.0%            (1) Table may not foot and percentages may not recalculate due to rounding.  Management Commentary Robert Leasure Jr., President and Chief Executive Officer, commented, “During the third quarter of fiscal 2025, we continued to make progress towards the financial goals we outlined during our investor day in May. We were pleased that revenue and margins improved over the second quarter, and the year over year quarterly revenue increase of 23.5% was in line with our expectations. "Our DSA net awards for the third quarter of fiscal 2025 increased 25% versus the same period last year, following a 27% year over year improvement in the second quarter. Much of this was driven by the benefits of the integration, optimization and start up investments we have implemented over the last two years. In particular, our Discovery, Medical Device, Biotherapeutics and Genetic Toxicology businesses have seen strong growth in quoting and awards over the last two quarters. "As we experience this growth in revenue and awards, we remain highly focused on client satisfaction and delivery of on-time, high quality products and services. We consistently monitor operational data and client metrics to help build a strong recurring client base. "This quarter’s results demonstrate continued progress in the execution of our strategic plans. We look forward to our future and want to thank all of our employees, shareholders and partners for their support and trust." Highlights Q3 FY 2025 Highlights Revenue was $130.7 million in Q3 FY 2025, an increase of $24.9 million, or 23.5%, compared to $105.8 million during the three months ended June 30, 2024 (“Q3 FY 2024”), driven by an increase of $21.0 million, or 34.1%, in Research Models and Services ("RMS") revenue and a $3.9 million, or 8.9%, increase in Discovery and Safety Assessment ("DSA") revenue.Consolidated net loss for Q3 FY 2025 was $17.6 million, or 13.5% of total revenue, compared to consolidated net loss of $26.1 million, or 24.7% of total revenue, in Q3 FY 2024.Adjusted EBITDA1 in Q3 FY 2025 was $11.6 million, or 8.9% of total revenue, compared to $0.1 million, or 0.1% of total revenue, in Q3 FY 2024.Book-to-bill ratio for Q3 FY 2025 was 1.07x for the DSA services business.DSA backlog was $134.3 million at June 30, 2025, compared to $139.4 million at June 30, 2024, and $130.8 million at March 31, 2025. YTD FY 2025 Highlights Revenue was $374.9 million in YTD FY 2025, an increase of $14.6 million, or 4.0%, compared to $360.3 million during the nine months ended June 30, 2024 (“YTD FY 2024”), driven by an increase of $13.8 million, or 6.1%, in RMS revenue and a $0.8 million, or 0.6%, increase in DSA revenue.Consolidated net loss for YTD FY 2025 was $60.1 million, or 16.0% of total revenue, compared to consolidated net loss of $90.0 million, or 25.0% of total revenue, in YTD FY 2024.Adjusted EBITDA1 in YTD FY 2025 was $22.1 million, or 5.9% of total revenue, compared to $12.8 million, or 3.6% of total revenue, in YTD FY 2024.Book-to-bill ratio for YTD FY 2025 was 1.03x for the DSA services business. 1 This is a non-GAAP financial measure. Refer to “Note on Non-GAAP Financial Measures” in this release for further information. Recent Developments On June 2, 2025, the Securities and Exchange Commission (the "SEC") provided notice to the Company, through the Company’s external counsel, that the SEC’s Division of Enforcement (the “Division”) has concluded its previously disclosed investigation related to non-human primate ("NHP") importations from Asia, including importation practices in accordance with the U.S. Foreign Corrupt Practices Act and, based on the information available to the Division as of the date of its letter, the Division does not intend to recommend an enforcement action by the SEC against the Company.During Q3 FY 2025, one property previously reported as held for sale was sold. One property remains under contract to be sold and is held for sale as of June 30, 2025, in connection with our U.S. optimization plan.As previously disclosed, the Company and certain of its current and former directors and officers have been named as defendants in a putative securities class action lawsuit and two consolidated shareholder derivative lawsuits. Although no agreements have been reached, based on current negotiations with the plaintiffs, the Company has recorded a $10.0 million accrual for these lawsuits as of June 30, 2025 and a $10.0 million receivable, as the Company currently expects to recover the full amount of the accrual under its existing insurance policies. Although these amounts have been recorded to date, there can be no assurance that final agreements will be reached, on these or other terms. Final amounts payable or recoverable related to these lawsuits may be materially different than the amounts recorded, and are subject to final resolution of these lawsuits, including negotiations between the Company, the other defendants and the plaintiffs, and required approvals by all parties involved and the courts. Third Quarter Fiscal 2025 Financial Results (Three Months Ended June 30, 2025) Revenue increased 23.5% to $130.7 million in Q3 FY 2025 as compared to $105.8 million in Q3 FY 2024. The higher total revenue in Q3 FY 2025 was driven by a $21.0 million increase in RMS revenue and a $3.9 million increase in DSA revenue. The increase in RMS revenue was due primarily to increased NHP-related product and service revenue. DSA revenue increased primarily due to an increase in general toxicology services revenue, as well as an increase in biotherapeutic services revenue and medical device services revenue. Operating loss was $5.7 million in Q3 FY 2025 as compared to $20.8 million in Q3 FY 2024. The decrease in operating loss was primarily driven by a change from RMS operating loss of $7.4 million in Q3 FY 2024 to RMS operating income of $6.4 million in Q3 FY 2025, an improvement of $13.8 million. The change in RMS operating income (loss) was primarily driven by the increase in revenue discussed above and decreased operating expenses, partially offset by increased cost of services provided and cost of products sold (collectively, "cost of revenue"). The decrease in operating expenses was primarily due to the $2.0 million charge related to the Resolution Agreement and Plea Agreement with the U.S. Department of Justice (the "DOJ") that was incurred during Q3 FY 2024, which did not repeat during Q3 FY 2025. The increase in cost of revenue primarily related to increased costs associated with the increased NHP-related product and service revenue discussed above. Fiscal 2025 Financial Results (Nine Months Ended June 30, 2025) Revenue increased 4.0% to $374.9 million in YTD FY 2025 as compared to $360.3 million in YTD FY 2024. The higher total revenue was primarily driven by a $13.8 million increase in RMS revenue. The increase in RMS revenue was primarily due to higher NHP-related product and service revenue. Operating loss was $24.1 million in YTD FY 2025 as compared to $73.2 million in YTD FY 2024. The decrease in operating loss was primarily driven by a change from RMS operating loss of $33.0 million in YTD FY 2024 to RMS operating income of $16.6 million in YTD FY 2025, an improvement of $49.6 million. The change in RMS operating income (loss) was primarily due to the $28.5 million charge related to the Resolution Agreement and Plea Agreement that was incurred during YTD FY 2024, which did not repeat during YTD FY 2025, the increase in RMS revenue discussed above and the $7.6 million settlement payment we received from Freese and Nichols Inc. ("FNI") during YTD FY 2025. Cash and cash equivalents was $6.2 million at June 30, 2025, compared to $21.4 million at September 30, 2024. Cash used in operating activities was $24.8 million for YTD FY 2025 compared to $4.4 million of cash used in operating activities for YTD FY 2024. For YTD FY 2025, capital expenditures totaled $13.9 million compared to $17.0 million for YTD FY 2024. Total debt, net of debt issuance costs, as of June 30, 2025, was $396.5 million compared to $393.3 million on September 30, 2024. As of June 30, 2025, there were no borrowings on the Company’s $15.0 million revolving credit facility. Recently, the Company has requested a draw of $3.0 million on its revolving credit facility. Webcast and Conference Call Management will host a conference call on Wednesday, August 6, 2025, at 4:30 pm ET to discuss third fiscal quarter of 2025 results.Interested parties may participate in the call by dialing: (800) 245-3047 (Domestic)(203) 518-9765(International)"INOTIV" (Conference ID) The live conference call webcast will be accessible in the Investors section of the Company’s web site and directly via the following link: https://viavid.webcasts.com/starthere.jsp?ei=1725515&tp_key=690c604cf0 For those who cannot listen to the live broadcast, an online replay will be available in the Investors section of Inotiv’s web site at: https://ir.inotiv.com/events-and-presentations/default.aspx. Note on Non-GAAP Financial Measures This press release contains financial measures that are not calculated in accordance with generally accepted accounting principles in the United States ("GAAP:), including Adjusted EBITDA and Adjusted EBITDA as a percentage of total revenue for the three and nine months ended June 30, 2025 and 2024 and selected business segment information for those periods. Adjusted EBITDA as reported herein refers to a financial measure that excludes from consolidated net loss statements of operations line items interest expense, net and income tax benefit, as well as non-cash charges for depreciation and amortization, stock compensation expense, startup costs, restructuring costs, unrealized foreign exchange (gain) loss, amortization of inventory step up, loss (gain) on disposition of assets, amounts received from the legal settlement with FNI, other unusual, third party costs and the charge in connection with the Resolution Agreement and Plea Agreement. The adjusted business segment information excludes from operating loss and unallocated corporate operating expenses for these same expenses. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in this press release. The Company believes that these non-GAAP measures provide useful information to investors. Among other things, they may help investors evaluate the Company’s ongoing operations. They can assist in making meaningful period-over-period comparisons and in identifying operating trends that would otherwise be masked or distorted by the items subject to the adjustments. Management uses these non-GAAP measures internally to evaluate the performance of the business, including to allocate resources. Investors should consider these non-GAAP measures as supplemental and in addition to, not as a substitute for or superior to, measures of financial performance prepared in accordance with GAAP. Management has chosen to provide this supplemental information to investors, analysts, and other interested parties to enable them to perform additional analyses of our results and to illustrate our results giving effect to the non-GAAP adjustments. Management strongly encourages investors to review the Company's condensed consolidated financial statements and publicly filed reports in their entirety and cautions investors that the non-GAAP measures used by the Company may differ from similar measures used by other companies, even when similar terms are used to identify such measures. About the Company Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs and medical devices to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical research and development projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here: https://www.inotiv.com/. This release contains forward-looking statements that are subject to risks and uncertainties including, but not limited to, statements regarding our intent, belief or current expectations with respect to (i) our strategic plans; (ii) trends in the demand for our services and products; (iii) trends in the industries that consume our services and products; (iv) market and company-specific impacts of NHP supply and demand matters; (v) compliance with the Resolution Agreement and Plea Agreement and the expected impacts on the Company related to the compliance plan and compliance monitor, and the expected amounts, timing and expense treatment of cash payments and other investments thereunder; (vi) our ability to service our outstanding indebtedness and to comply or regain compliance with financial covenants, including those established by the Seventh Amendment to our Credit Agreement; (vii) our current and forecasted cash position; (viii) our ability to make capital expenditures, fund our operations and satisfy our obligations; (ix) our ability to manage recurring and unusual costs; (x) our ability to execute on and realize the expected benefits related to our restructuring and site optimization plans; (xi) our expectations regarding the volume of new bookings, pre-sales, pricing, cost savings initiatives, expansion of services, operating income or losses and liquidity; (xii) our ability to effectively fill the recent expanded capacity or any future expansion or acquisition initiatives undertaken by us; (xiii) our ability to develop and build infrastructure and teams to manage growth and projects; (xiv) our ability to continue to retain and hire key talent; (xv) our ability to market our services and products under our corporate name and relevant brand names; (xvi) our ability to develop new services and products; (xvii) our ability to negotiate amendments to the Credit Agreement or obtain waivers related to the financial covenants defined within the Credit Agreement; (xviii) the potential outcome of litigation against us, including any settlement and amounts accrued or recoverable; and (xix) the impact of macroeconomic factors, including but not limited to tariffs, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission. Further discussion of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in our Annual Report on Form 10-K as filed on December 4, 2024, as well as other filings we make with the Securities and Exchange Commission. Company ContactInvestor RelationsInotiv, Inc.LifeSci AdvisorsBeth A. Taylor, Chief Financial OfficerSteve Halper(765) 497-8381(646) 876-6455beth.taylor@inotiv.comshalper@lifesciadvisors.com INOTIV, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share amounts)(unaudited)     Three Months EndedJune 30, Nine Months EndedJune 30, 2025 2024 2025 2024Service revenue$59,579  $54,364  $169,264  $165,188 Product revenue 71,104   51,422   205,618   195,134 Total revenue$130,683  $105,786  $374,882  $360,322 Costs and expenses:       Cost of services provided (excluding depreciation and amortization of intangible assets) 42,983   39,622   125,719   117,362 Cost of products sold (excluding depreciation and amortization of intangible assets) 53,778   45,083   161,212   161,728 Selling 5,530   5,030   15,745   15,781 General and administrative 17,879   16,782   54,183   56,505 Depreciation and amortization of intangible assets 13,985   14,119   41,988   42,524 Other operating expense 2,203   5,902   155   39,661 Operating loss$(5,675) $(20,752) $(24,120) $(73,239)Other (expense) income:       Interest expense, net (13,606)  (12,116)  (40,890)  (34,568)Other income (expense) 519   (82)  464   1,092 Loss before income taxes$(18,762) $(32,950) $(64,546) $(106,715)Income tax benefit 1,185   6,863   4,473   16,721 Consolidated net loss$(17,577) $(26,087) $(60,073) $(89,994)Less: Net loss attributable to noncontrolling interests —   —   —   (440)Net loss attributable to common shareholders$(17,577) $(26,087) $(60,073) $(89,554)        Loss per common share       Net loss attributable to common shareholders:       Basic$(0.51) $(1.00) $(1.89) $(3.46)Diluted$(0.51) $(1.00) $(1.89) $(3.46)Weighted-average number of common shares outstanding:       Basic 34,353   25,993   31,811   25,862 Diluted 34,353   25,993   31,811   25,862          INOTIV, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands, except share amounts)     June 30, September 30, 2025 2024    Assets   Current assets:   Cash and cash equivalents$6,215  $21,432 Trade receivables and contract assets, net of allowances for credit losses of $6,445 and $6,931, respectively 78,745   73,560 Inventories, net 45,074   18,173 Prepaid expenses and other current assets 43,535   50,248 Assets held for sale 2,016   — Total current assets 175,585   163,413     Property and equipment, net 182,335   188,328 Operating lease right-of-use assets, net 44,930   49,165 Goodwill 94,286   94,286 Other intangible assets, net 248,930   274,396 Other assets 13,671   11,773 Total assets$759,737  $781,361     Liabilities and shareholders' equity   Current liabilities:   Accounts payable$45,373  $33,526 Accrued expenses and other current liabilities 35,921   28,218 Fees invoiced in advance 40,251   41,986 Current portion of long-term operating lease 8,845   11,774 Current portion of long-term debt 6,206   3,538 Total current liabilities 136,596   119,042 Long-term operating leases, net 40,085   40,010 Long-term debt, less current portion, net of debt issuance costs 390,336   389,801 Other long-term liabilities 27,566   34,963 Deferred tax liabilities, net 21,369   27,041 Total liabilities 615,952   610,857     Shareholders’ equity:   Common shares, no par value:   Authorized 74,000,000 shares at June 30, 2025 and at September 30, 2024; 34,354,251 issued and outstanding at June 30, 2025 and 26,015,129 at September 30, 2024 8,550   6,466 Additional paid-in capital 754,723   724,789 Accumulated deficit (622,261)  (562,163)Accumulated other comprehensive income 2,773   1,412 Total equity 143,785   170,504 Total liabilities and shareholders’ equity$759,737  $781,361  INOTIV, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(in thousands)(unaudited)   Nine Months EndedJune 30, 2025 2024Operating activities:   Consolidated net loss$(60,073) $(89,994)Adjustments to reconcile net loss to net cash used in operating activities:   Depreciation and amortization 41,988   42,524 Employee stock compensation expense 4,644   5,118 Changes in deferred taxes (5,835)  (17,407)Provision for expected credit losses (451)  (1,282)Amortization of debt issuance costs and original issue discount 3,862   2,575 Non-cash interest and accretion expense 9,176   5,553 Other non-cash operating activities 1,083   (711)Changes in operating assets and liabilities:   Trade receivables and contract assets (4,338)  24,876 Inventories (26,846)  17,520 Prepaid expenses and other current assets 6,877   942 Operating lease right-of-use assets and liabilities, net 1,382   1,092 Accounts payable 11,384   (4,931)Accrued expenses and other current liabilities 3,340   2,254 Fees invoiced in advance (1,868)  (17,017)Other asset and liabilities, net (9,085)  24,455 Net cash used in operating activities (24,760)  (4,433)    Investing activities:   Capital expenditures (13,938)  (17,015)Proceeds from sale of property and equipment 1,522   5,432 Net cash used in investing activities (12,416)  (11,583)    Financing activities:   Payments on revolving credit facility (20,000)  — Payments on senior term notes and delayed draw term loans (4,254)  (2,073)Borrowings on revolving credit facility 20,000   — Issuance of common shares 27,524   — Other financing activities, net (1,187)  (2,816)Net cash provided by (used in) financing activities 22,083   (4,889)    Effect of exchange rate changes on cash and cash equivalents (124)  (153)    Net decrease in cash and cash equivalents (15,217)  (21,058)Cash and cash equivalents at beginning of period 21,432   35,492 Cash and cash equivalents at end of period$6,215  $14,434     Supplemental disclosure of cash flow information:   Cash paid for interest 30,950  $27,398 Income taxes paid, net 714  $1,517  INOTIV, INC.RECONCILIATION OF GAAP TO NON-GAAPSELECT BUSINESS SEGMENT INFORMATION(In thousands)(Unaudited)     Three Months Ended June 30, Nine Months Ended June 30, 2025 2024 2025 2024DSA       Revenue48,150  44,219  136,304  135,548 Operating income2,149  2,325  4,039  6,771 Operating income as a % of total revenue1.6% 2.2% 1.1% 1.9%Add back:       Depreciation and amortization4,444  4,488  13,543  13,260 Restructuring costs (1)—  205  —  341 Startup costs (2)591  772  1,708  2,569 Total non-GAAP adjustments to operating income5,035  5,465  15,251  16,170 Non-GAAP operating income7,184  7,790  19,290  22,941 Non-GAAP operating income as a % of DSA revenue14.9% 17.6% 14.2% 16.9%Non-GAAP operating income as a % of total revenue5.5% 7.4% 5.1% 6.4%        RMS       Revenue82,533  61,567  238,578  224,774 Operating income (loss)6,378  (7,447) 16,625  (32,973)Operating income (loss) as a % of total revenue4.9% (7.0%) 4.4% (9.2%)Add back:       Depreciation and amortization9,365  9,401  27,953  28,781 Restructuring costs (1)145  252  1,378  2,518 Amortization of inventory step up—  49  —  209 Legal Settlement (3)—  —  (7,550) — Other unusual, third party costs (4)966  2,270  3,444  4,628 Resolution Agreement and Plea Agreement—  2,000  —  28,500 Total non-GAAP adjustments to operating income (loss)10,476  13,972  25,225  64,636 Non-GAAP operating income16,854  6,525  41,850  31,663 Non-GAAP operating income as a % of RMS revenue20.4% 10.6% 17.5% 14.1%Non-GAAP operating income as a % of total revenue12.9% 6.2% 11.2% 8.8%        Unallocated Corporate Operating Loss(14,202) (15,630) (44,784) (47,037)Unallocated corporate operating loss as a % of total revenue(10.9)        % (14.8)        % (11.9)        % (13.1)        %Add back:       Depreciation and amortization176  230  492  483 Stock compensation expense1,439  1,337  4,644  5,118 Acquisition and integration costs—  —  —  70 Total non-GAAP adjustments to operating loss1,615  1,567  5,136  5,671 Non-GAAP operating loss(12,587) (14,063) (39,648) (41,366)Non-GAAP operating loss as a % of total revenue(9.6)        % (13.3)        % (10.6)        % (11.5)        %        Total       Revenue130,683  105,786  374,882  360,322 Operating loss(5,675) (20,752) (24,120) (73,239)Operating loss as a % of total revenue(4.3)        % (19.6)        % (6.4)        % (20.3)        %Add back:       Depreciation and amortization13,985  14,119  41,988  42,524 Stock compensation expense1,439  1,337  4,644  5,118 Restructuring costs (1)145  457  1,378  2,859 Acquisition and integration costs—  —  —  70 Amortization of inventory step up—  49  —  209 Startup costs (2)591  772  1,708  2,569 Legal Settlement (3)—  —  (7,550) — Other unusual, third party costs (4)966  2,270  3,444  4,628 Resolution Agreement and Plea Agreement (5)—  2,000  —  28,500 Total non-GAAP adjustments to operating loss17,126  21,004  45,612  86,477 Non-GAAP operating income11,451  252  21,492  13,238 Non-GAAP operating income as a % of total revenue8.8% 0.2% 5.7% 3.7%             Adjustments to certain GAAP reported measures for the three and nine months ended June 30, 2025 and 2024 include, but are not limited to, the following: (1) For the three and nine months ended June 30, 2025, primarily represents non-cash impairment charges incurred in connection with the exit of multiple sites. For the three and nine months ended June 30, 2024, primarily represents costs incurred in connection with the exit of multiple sites and the enablement of the in-house integration of Inotiv’s North American transportation operations.(2) For the three and nine months ended June 30, 2025 and 2024, primarily represents costs related to the development and initiation of new service offerings that are not yet revenue generating for the respective periods.(3) For the nine months ended June 30, 2025, represents the settlement payment we received from FNI.(4) For the three and nine months ended June 30, 2025, primarily represents third party and legal costs incurred in connection with the Resolution Agreement and Plea Agreement and fees incurred in connection with the FNI settlement discussed above. For the three and nine months ended June 30, 2024, primarily represents legal costs incurred in connection with the DOJ investigation and certain remediation costs. (5) For the three and nine months ended June 30, 2024, represents a charge related to the Resolution Agreement and Plea Agreement related to the DOJ investigation.  INOTIV, INC.RECONCILIATION OF GAAP NET LOSS TO NON-GAAP ADJUSTED EBITDA(In thousands)(Unaudited)     Three Months EndedJune 30, Nine Months EndedJune 30, 2025 2024 2025 2024GAAP Consolidated Net Loss$(17,577) $(26,087) $(60,073) $(89,994)Adjustments       Interest expense, net 13,606   12,116   40,890   34,568 Income tax benefit (1,185)  (6,863)  (4,473)  (16,721)Depreciation and amortization 13,985   14,119   41,988   42,524 Stock compensation expense 1,439   1,337   4,644   5,118 Startup costs (1) 591   772   1,708   2,569 Restructuring costs (2) 145   457   1,378   2,859 Unrealized foreign exchange (gain) loss (527)  33   (43)  (576)Amortization of inventory step up —   49   —   209 Loss (gain) on disposition of assets 133   (79)  230   (938)Legal Settlement (3) —   —   (7,550)  — Other unusual, third party costs (4) 966   2,270   3,444   4,698 Resolution Agreement and Plea Agreement (5) —   2,000   —   28,500 Adjusted EBITDA$11,576  $124  $22,143  $12,816 GAAP consolidated net loss as a percent of total revenue(13.5)% (24.7)% (16.0)% (25.0)%Adjustments as a percent of total revenue 22.3%  24.8%  21.9%  28.5%Adjusted EBITDA as a percent of total revenue 8.9%  0.1%  5.9%  3.6%                 Adjustments to certain GAAP reported measures for the three and nine months ended June 30, 2025 and 2024 include, but are not limited to, the following: (1) For the three and nine months ended June 30, 2025 and 2024, primarily represents costs related to the development and initiation of new service offerings that are not yet revenue generating for the respective periods.(2) For the three and nine months ended June 30, 2025, primarily represents non-cash impairment charges incurred in connection with the exit of multiple sites. For the three and nine months ended June 30, 2024, primarily represents costs incurred in connection with the exit of multiple sites and the enablement of the in-house integration of Inotiv’s North American transportation operations.(3) For the nine months ended June 30, 2025, represents the settlement payment we received from FNI.(4) For the three and nine months ended June 30, 2025, primarily represents third party and legal costs incurred in connection with the Resolution Agreement and Plea Agreement and fees incurred in connection with the FNI settlement discussed above. For the three and nine months ended June 30, 2024, primarily represents legal costs incurred in connection with the DOJ investigation and certain remediation costs. (5) For the three and nine months ended June 30, 2024, represents a charge related to the Resolution Agreement and Plea Agreement related to the DOJ investigation.

Related News